Chimeric Therapeutics (ASX:CHM) Debt-to-Revenue : N/A (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Chimeric Therapeutics Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Chimeric Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was A$0.00 Mil. Chimeric Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was A$0.00 Mil. Chimeric Therapeutics's annualized Revenue for the quarter that ended in Dec. 2023 was A$0.00 Mil.

Chimeric Therapeutics Debt-to-Revenue Historical Data

The historical data trend for Chimeric Therapeutics's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chimeric Therapeutics Debt-to-Revenue Chart

Chimeric Therapeutics Annual Data

Trend

Jun21

Jun22

Jun23

Debt-to-Revenue

N/A

Chimeric Therapeutics Semi-Annual Data
	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Revenue	Get a 7-Day Free Trial			N/A	N/A	N/A	N/A	N/A

Competitive Comparison of Chimeric Therapeutics's Debt-to-Revenue

For the Biotechnology subindustry, Chimeric Therapeutics's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Chimeric Therapeutics's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chimeric Therapeutics's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Chimeric Therapeutics's Debt-to-Revenue falls into.

Chimeric Therapeutics Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Chimeric Therapeutics's Debt-to-Revenue for the fiscal year that ended in Jun. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(0	+	0)	/	N/A
	=	N/A

Chimeric Therapeutics's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(0	+	0)	/	0
	=	N/A

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is two times the quarterly (Dec. 2023) Revenue data.

Chimeric Therapeutics Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Chimeric Therapeutics's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Chimeric Therapeutics (ASX:CHM) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chimeric Therapeutics Ltd (ASX:CHM) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

CHMMF:USA

Address

62 Lygon Street, Level 3, Carlton South, Melbourne, VIC, AUS, 3053

Website

https://www.chimerictherapeutics.com

Chimeric Therapeutics Ltd is a biotechnology company engaged in developing a cancer cell therapy drug. Its technology CLTX-CAR T uses chlorotoxin, a peptide discovered in scorpion venom, as the tumor-targeting component of the CAR to reprogram T cells. Primary products under development by the company are NK Cell Derived Allogenic Therapies and T Cell Derived Autologous Therapies. The company has one segment being the research, development and commercialization of health technologies.

Chimeric Therapeutics (ASX:CHM) Headlines

No Headlines